Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00727532 · ClinicalTrials.gov registry record · NA
Sorafenib in Treating Patients With Locally Advanced or Metastatic Kidney Cancer
A NA study, sponsored by Northwestern University.
- Terminated
- Registry status
- NA
- Development phase
- 9
- Enrollment target
NCT00727532 is a NA study that was terminated before completion, run by Northwestern University. The registered enrollment target is 9 participants.
The verdict
NCT00727532, a NA study, was terminated before completion, sponsored by Northwestern University.
- TERMINATED
- Registry status
- NA
- Development phase
- 9 participants
- Enrollment target
Study Summary
RATIONALE: Sorafenib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth and by blocking blood flow to the tumor. Giving sorafenib before surgery may make the tumor smaller and reduce the amount of normal tissue that needs to be removed. PURPOSE: This clinical trial is studying how well sorafenib works in treating patients with locally advanced or metastatic kidney cancer.
Interventions
- DRUG Sorafenib
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 9 participants |
| Start Date | 2008-07 |
| Est. Completion | 2013-09 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00727532
The ClinicalTrials.gov registry entry for NCT00727532 describes a study currently listed as terminated, categorized as NA. The registered enrollment target is 9 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Northwestern University, which has 1,209 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Sorafenib is the first listed.
NCT00727532 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00727532 about?
NCT00727532 is a clinical study titled "Sorafenib in Treating Patients With Locally Advanced or Metastatic Kidney Cancer". RATIONALE: Sorafenib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth and by blocking blood flow to the tumor. Giving sorafenib before surgery may make the tumor smaller and reduce the amount of normal tissue that needs to be removed. PURPOSE: This clinical ...
What is the current status of trial NCT00727532?
This trial is currently terminated. It is a NA study. The enrollment target is 9 participants. The study started on 2008-07. Estimated completion is 2013-09.
What interventions are being tested in trial NCT00727532?
The interventions under investigation include: Sorafenib (DRUG).
Who is sponsoring clinical trial NCT00727532?
This trial is sponsored by Northwestern University, which has 1,209 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.